Investor News / RNS

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG.   This project will use PK/PD modelling and simulation approaches to inform understanding and selection of appropriate clinical dosing for a First In Human (“FiH”) study for an...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that its Total Income and Loss after Tax will exceed market expectations for the financial year ending 30 June 2025 (FY25).   Based on unaudited end of year accounts for FY25, the Company is projecting to finish the year with...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the implementation of the Company’s personalised dosing software onto the DoseMeRx platform and the expansion of its partnership with DoseMe to support the development of new dosing solutions.   Following several iterations of software deployment, evaluation and debugging, the Company...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract award with an existing client.   In this new project, Physiomics will apply PK/PD modelling and simulation expertise to support preclinical-to-clinical translation for one of the client’s lead candidates and inform selection of human dosing schemes for...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the recruitment of Mr Jesse Thissen as Head of Biometrics, as well as the signing of the Company’s first ever two Biometrics contracts.   Contract Award The two new contracts are with a UK headquartered clinical-stage biopharmaceutical company developing immunotherapies that...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a sizeable contract extension award with an existing large pharma client.   The project builds upon the contract award announced on 13 June 2024, where the Company’s proprietary Virtual Tumour platform has been used to model the client’s targeted oncology...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new UK client.   The project will involve the application of population Pharmacokinetic (PK) modelling techniques using Phase 1 data to inform the Phase 2 study of a small molecule designed to treat rheumatoid arthritis....

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new UK client.   The project will involve the application of modelling and simulation techniques to support the development of a first-in-class bifunctional antibody therapy designed to target multiple solid tumour indiciations. More specifically, Pharmacokinetic...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the joint online publication in collaboration with Ankyra Therapeutics entitled ‘A pharmacokinetic and pharmacodynamic model of an interleukin-12 (IL-12) anchored-drug conjugate for the treatment of solid tumors’ in the Journal of Molecular Cancer Therapeutics, American Association for Cancer...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its long-standing client, Numab Therapeutics AG.   The project will involve the application of modelling and simulation techniques to inform pre-clinical development of a multi-specific antibody designed to activate anti-tumor immune responses for the treatment of...